利伐沙班医保吗？

Rivaroxaban tablets are produced by Bayer Healthcare of Germany and are used to prevent venous thrombosis (VTE) in adult patients undergoing elective hip or knee replacement surgery. It is used to treat venous thrombosis (DVT) in adults and reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT. For use in adult patients with non-valvular atrial fibrillation who have one or more risk factors (e.g., congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, history of stroke or transient ischemic attack) to reduce the risk of stroke and systemic embolism.

Rivaroxaban is a highly selective, oral drug that directly inhibits factor Xa. By inhibiting factor Rivaroxaban does not inhibit thrombin (activated factor II) and has no proven effect on platelets. In China, rivaroxaban tablets were approved for sale by the State Food and Drug Administration in March 2009. Although this drug is effective and easy to use, some patients think it is a bit expensive in terms of price. Therefore, some patients often ask their medical companions whether rivaroxaban is covered by medical insurance?

It is understood that Bayer launched rivaroxaban into China in 2009, which coincided with the last round of adjustments to the national medical insurance directory. In the same year, rivaroxaban took advantage of this train and successfully entered the national medical insurance directory. In that adjustment, rivaroxaban was added to the medical insurance catalog as "limited to lower limb joint replacement surgery".

The price of rivaroxaban in medical insurance is: pharmaceutical specification: 10mg-5 tablets/box, the price in domestic pharmacies is about 138$; pharmaceutical specification: 15mg-7 tablets/box, the price in domestic pharmacies is 195$; pharmaceutical specification: 20mg-7 tablets/box, the price in domestic pharmacies is 245$. The reimbursement ratio of rivaroxaban in different regions is different. It is recommended that patients consult the local pharmacy and hospital.